National Comprehensive Cancer Network (NCCN) guidelines recommend BRAF testing to distinguish between sporadic MLH1 deficient tumors caused by promoter methylation with associated BRAF mutations and loss of MLH1 expression in Lynch syndrome tumors by germline mutation and absence of BRAF mutations [29]. This evidence concerns the gene BRAF and Lynch syndrome.